Drugs / MUC1 Peptide Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00640861 | Aug 2008 → Apr 2015 | female breast carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06218303 | Feb 2024 → Aug 2026 overdue | ductal breast carcinoma in situ | Finn, Olivera, PhD | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC1 Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06218303 ↗ |
| Modality | Vaccine | “MUC1 and HER-2/neu peptide vaccines” NCT00640861 ↗ |
| Route | Subcutaneous | “Patients receive a vaccine comprising incomplete Freund's adjuvant, MUC1 antigen vaccine, two Her-2/neu peptide-based vaccines, and sargramostim (GM-CSF) subcutaneously (SC) on day 1.” NCT00640861 ↗ |
| Target | MUC1 | “A Clinical Study of a Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma in Situ” NCT06218303 ↗ |